MARKET WIREReuters • 3h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why ORIC Stock dropped -3.33% Today — RQD Quant Desk Flash
$8.99 -3.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.92
Oric Pharmaceuticals Inc. (ORIC) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $931.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ORIC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ORIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $8.99 (-3.33% 1D, market cap $931.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ORIC ranks #664 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ORIC compare to AKTS and CYRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORIC carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -33.4%. By comparison, AKTS (Aktis Oncology Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $937.2M) and CYRX (CryoPort Inc.) posts a D- grade (38/100 RQD, P/E 11.8x, ROIC -11.5%, cap $926.4M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ORIC?
▼
Per ORIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001796280), Oric Pharmaceuticals Inc. generated $0 in revenue, -$129.5M in net income, and -$111.7M in free cash flow against $408.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.92 (-0.79%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORIC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY ORIC SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (31% of score)
FRED Regime × Technicals: 24% of 52W Range • RSI-14 at 33 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$11.99+3% Next Q
47
Q2 (-2Q)Grade D$12.35+6.6% Next Q
44
Q3 (-1Q)Grade D$13.17-31.7% Next Q
42
CurrentGrade D-$8.99-7.6% Hist 90D α
39
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ORIC Turnaround Squeeze
While ORIC currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.46) and Max Pain ($9.44) forces dealer call-delta covering toward $15.41.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORIC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ORIC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ORIC Stock dropped -3.33% Today — RQD Quant Desk Flash
Oric Pharmaceuticals Inc. (ORIC) dropped -3.33% to $8.99, trading at 24% of its 52-week range ($7.23 – $14.68). Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 24% of its 52-week range ($7.23 – $14.68) with RSI-14 at 33 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.99 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ORIC Headlines & Catalysts
MARKET WIREReuters • 3h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 4h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 6h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 8h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 8h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 10h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 11h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORIC)
- ✓Walkthrough of ORIC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ORIC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.01%▼ SUPPORT BREAKDOWN
2026-10-30O $8.87H $9.80L $8.27C $8.99VOL 2.44M
RES: $14.24SUP: $11.09SMA50: $12.46SMA200: $11.14
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ORIC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ORIC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ORIC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ORIC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORIC)
Health Care Rank #664 of 1016
⚔️ AKTS vs ORIC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ORIC vs. AKTS, CYRX, KURA, ANRO)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Oric Pharmaceuticals Inc. (ORIC) ranks #664 by composite RQD confidence (39/100, grade D-) and #371 by equity capitalization ($931.8M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with ORIC at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ORIC
ACTIVE
Oric Pharmaceuticals Inc. | D- | 39/100 | — | — | -33.4% | -3.33% | $931.8M | Benchmark Subject |
| AKTS Aktis Oncology Inc. | D+ | 56/100 | — | — | — | +0.18% | $937.2M | /akts-vs-oric → |
| CYRX CryoPort Inc. | D- | 38/100 | 11.8x | 47.1% | -11.5% | -1.88% | $926.4M | /cyrx-vs-oric → |
| KURA Kura Oncology Inc. | E | 29/100 | — | — | -35.0% | -1.49% | $939.4M | /kura-vs-oric → |
| ANRO Alto Neuroscience Inc. | D- | 38/100 | — | — | -35.0% | +0.60% | $921.0M | /anro-vs-oric → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001796280In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oric Pharmaceuticals Inc. (ORIC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$129.5M, operating cash flow of -$111.0M, and free cash flow of -$111.7M (+1.9% YoY). On the balance sheet, ORIC closed FY2025 with $408.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$129.5M | -$111.0M | -$111.7M | $408.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$127.8M | -$112.7M | -$113.8M | $274.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$100.7M | -$85.7M | -$85.7M | — | — |
3. ORIC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ORIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Oric Pharmaceuticals Inc. (NASDAQ: ORIC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $8.99 (-3.33% 1D, market cap $931.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ORIC ranks #664 in composite RQD confidence.
How does ORIC compare to AKTS and CYRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORIC carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -33.4%. By comparison, AKTS (Aktis Oncology Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $937.2M) and CYRX (CryoPort Inc.) posts a D- grade (38/100 RQD, P/E 11.8x, ROIC -11.5%, cap $926.4M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ORIC?
Per ORIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001796280), Oric Pharmaceuticals Inc. generated $0 in revenue, -$129.5M in net income, and -$111.7M in free cash flow against $408.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ORIC trading relative to its 50-day, 200-day, and 52-week technical levels?
ORIC last traded at $8.99 (-3.33% on volume of 1,046,832 shares), positioning the stock -27.85% below its 50-day simple moving average ($12.46) and -19.30% below its 200-day simple moving average ($11.14). Across its 52-week range of $7.23 to $14.68, ORIC sits at the 23.6% percentile with a 14-day RSI of 33.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.87 to $10.11).
ORIC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ORIC stock moving today?
Why ORIC Stock dropped -3.33% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-33% return on capital) under elevated 10-year interest-rate pressure.